Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Fordadistrogene-movaparvovec (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
Most Recent Events
- 18 Apr 2025 Planned End Date changed from 15 May 2039 to 29 Aug 2025.
- 18 Apr 2025 Planned primary completion date changed from 15 May 2039 to 29 Aug 2025.
- 07 Feb 2025 Status changed from recruiting to active, no longer recruiting.